Literature DB >> 9460552

Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins.

D S Wilbur1, P S Stayton, R To, K R Buhler, L A Klumb, D K Hamlin, J E Stray, R L Vessella.   

Abstract

In this investigation, a comparison of wild type recombinant streptavidin (r-SAv) with two genetically engineered mutant r-SAv proteins was undertaken. The investigation also included a comparison of the r-SAv with two streptavidin (SAv) proteins from commercial sources. In vitro characterization of the SAv proteins was conducted by HPLC, SDS-PAGE, IEF, and electrospray mass spectral analyses. All SAv proteins studied appeared to be a single species by size exclusion chromatography (HPLC) and SDS-PAGE analyses, but multiple species were noted in the IEF and MS analyses. In vivo comparisons of the SAv proteins were accomplished with dual isotope-labeled SAv in athymic mice. In an initial experiment, tissue localization of r-[131I]SAv directly radiolabeled using chloramine-T was compared with r-SAv radiolabeled with the N-hydroxysuccinimidyl p-iodobenzoate conjugate ([125I]-PIB), a radioiodination reagent that has been shown to result in iodine-labeled proteins which are stable to in vivo deiodination. The data obtained indicated that there is little difference in the distribution (except kidney localization) when r-SAv labeled by the two methods. Data obtained from comparison of r-[131I]SAv with a disulfide-stabilized r-SAv mutant (r-SAv-H127C), a C-terminal cysteine-containing r-SAv mutant (r-[125I]SAv-S139C), and two 125I-labeled SAv proteins obtained from commercial sources indicated that their distributions were quite similar, except the kidney concentrations were generally lower than that of r-[131I]SAv. On the basis of the similar distributions of the SAv proteins studied, it appears that the r-SAv mutants may be interchanged for the (wild type) r-SAv in pretargeting studies. Further, the similarity of distributions with two commercially available SAv proteins suggests that the results obtained in our studies and those of other groups may be directly compared (with consideration of animal model, sacrifice time, etc.).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460552     DOI: 10.1021/bc970152s

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  4 in total

1.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

2.  Rhizavidin from Rhizobium etli: the first natural dimer in the avidin protein family.

Authors:  Satu H Helppolainen; Kirsi P Nurminen; Juha A E Määttä; Katrin K Halling; J Peter Slotte; Tuulia Huhtala; Timo Liimatainen; Seppo Ylä-Herttuala; Kari J Airenne; Ale Närvänen; Janne Jänis; Pirjo Vainiotalo; Jarkko Valjakka; Markku S Kulomaa; Henri R Nordlund
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

3.  Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

Authors:  Yawen Li; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert Vessella; D Scott Wilbur
Journal:  Nucl Med Biol       Date:  2020-05-03       Impact factor: 2.408

4.  Internalization of novel non-viral vector TAT-streptavidin into human cells.

Authors:  Johanna Rinne; Brian Albarran; Juulia Jylhävä; Teemu O Ihalainen; Pasi Kankaanpää; Vesa P Hytönen; Patrick S Stayton; Markku S Kulomaa; Maija Vihinen-Ranta
Journal:  BMC Biotechnol       Date:  2007-01-02       Impact factor: 2.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.